1185237-08-4

1185237-08-4 structure

Name: rac Fesoterodine-d14 Fumarate
Chemical Name: rac Fesoterodine-d14 Fumarate
CAS Number: 1185237-08-4
Molecular Formula: C₃₀H₂₇D₁₄NO₇
Molecular Weight: 541.73500
Catalog: Signaling Pathways GPCR/G Protein mAChR
Create Date: 2016-07-13 05:46:04
Modify Date: 2026-07-11 13:54:09
(Rac)-Fesoterodine-d14 fumarate is a labelled racemic Fesoterodine. Fesoterodine is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine is used for the overactive bladder (OAB)[1][2].

Name	rac Fesoterodine-d14 Fumarate
Synonyms	[2H14]- (±)-Fesoterodine Fumate Fesoterodine-D14 FuMate SMP 8272-d14 SPM 907-d14 rac-Fesoterodine-d14 fumate [2-[3-[bis(1,1,1,2,3,3,3-heptadeuteriopropan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate,(E)-but-2-enedioic acid rac Fesoterodine-d14 Fumate 2-Methylpropanoic Acid 2-[rac-3-[Bis(1-Methylethyl-d7)amino]-1-phenylpropyl] -4-(hydroxyMethyl)phenyl Ester (2E)-2-Butenedioate

Description	(Rac)-Fesoterodine-d14 fumarate is a labelled racemic Fesoterodine. Fesoterodine is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine is used for the overactive bladder (OAB)[1][2].
Related Catalog	Signaling Pathways >> Neuronal Signaling >> mAChR Signaling Pathways >> GPCR/G Protein >> mAChR Research Areas >> Metabolic Disease Research Areas >> Neurological Disease
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Ellsworth P, et al. Fesoterodine for the treatment of urinary incontinence and overactive bladder. Ther Clin Risk Manag. 2009;5:869-76. Epub 2009 Nov 18. [3]. Didem Yilmaz-Oral, et al. The Beneficial Effect of Fesoterodine, a Competitive Muscarinic Receptor Antagonist on Erectile Dysfunction in Streptozotocin-induced Diabetic Rats [4]. Peter Ney, et al. Pharmacological Characterization of a Novel Investigational Antimuscarinic Drug, Fesoterodine, in Vitro and in Vivo. BJU Int. 2008 Apr;101(8):1036-42. [5]. Martin C Michel, et al. Fesoterodine: A Novel Muscarinic Receptor Antagonist for the Treatment of Overactive Bladder Syndrome. Expert Opin Pharmacother. 2008 Jul;9(10):1787-96.

Molecular Formula	C₃₀H₂₇D₁₄NO₇
Molecular Weight	541.73500
Exact Mass	541.37600
PSA	124.37000
LogP	5.09290

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

1251090-80-8	1251077-28-7
1249949-94-7	1247583-83-0
1305974-87-1	1390019-61-0
1249545-88-7	1251093-34-1
1249973-13-4	1248246-03-8